Publicaciones en las que colabora con Pablo Sarobe Ugarriza (23)

2024

  1. Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

2022

  1. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination

    Frontiers in Immunology, Vol. 13

  2. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer

    Frontiers in Immunology, Vol. 13

  3. Neoantigens as potential vaccines in hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 2

  4. TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity

    Cancer Letters, Vol. 528, pp. 45-58

  5. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?

    International Journal of Molecular Sciences, Vol. 23, Núm. 4

2021

  1. Advances in immunotherapy for hepatocellular carcinoma

    Nature Reviews Gastroenterology and Hepatology, Vol. 18, Núm. 8, pp. 525-543

  2. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

    British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149

2020

  1. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens

    Journal for immunotherapy of cancer, Vol. 8, Núm. 1

2019

  1. Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies

    Frontiers in Immunology, Vol. 10

  2. Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma

    Journal of Vascular and Interventional Radiology, Vol. 30, Núm. 7, pp. 1098-1105

2018

  1. Immunomodulatory properties of carvone inhalation and its effects on contextual fear memory in mice

    Frontiers in Immunology, Vol. 9, Núm. JAN

  2. The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer

    OncoImmunology, Vol. 7, Núm. 4

2017

  1. Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor

    Oncotarget, Vol. 8, Núm. 42, pp. 71709-71724

  2. Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy

    Cancer Research, Vol. 77, Núm. 13, pp. 3672-3684

  3. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination

    Oncotarget, Vol. 8, Núm. 2, pp. 2659-2671

2015

  1. Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

    Journal of Immunology, Vol. 195, Núm. 7, pp. 3180-3189

2011

  1. International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010

    Cancer Immunology, Immunotherapy

2007

  1. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ

    International Journal of Cancer, Vol. 121, Núm. 6, pp. 1282-1295

2001

  1. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine

    Journal of Hepatology, Vol. 35, Núm. 1, pp. 105-111